Pfizer-BioNTech and Moderna to earn $14.7B from COVID-19 vaccines sales by 2023

Pfizer-BioNTech and Moderna to earn $14.7B from COVID-19 vaccines sales by 2023

The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the lion's share of 2021 vaccine sales.



According to data presented by Finaria.it, BioNTech-Pfizer and Moderna COVID-19 vaccines sales are expected to generate $14.7bn in revenue by 2023.



Moderna COVID-19 Vaccine Sales Revenue to hit $3.5B in 2021



The call for COVID-19 vaccines and treatments has become louder than ever, with countries worldwide facing the full force of the pandemic's second wave.



As of January 11, there were over one thousand drugs and vaccines in development targeting the coronavirus disease, revealed the Pharma Intelligence data. More than 60% of them were still in the preclinical phase. However, three candidates were in the pre-registration phase, one candidate registered, and another ten were launched.



On December 2, 2020, the United Kingdom became the first Western country to approve any COVID-19 vaccine when it authorized the Pfizer-BioNTech candidate. The first doses were delivered to British seniors on December 8, 2020. The United States followed as Americans received initial shots